Barclays
ENFN

Barclays’s Enfusion, Inc. ENFN Stock Holding History

Barclays’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,948
Closed -$947K – 5646
2025
Q1 		$947K Sell
84,948
-9,193
-10% -$102K ﹤0.01% 3143
2024
Q4 		$970K Buy
94,141
+8,102
+9% +$78.3K ﹤0.01% 3399
2024
Q3 		$817K Buy
86,039
+61,554
+251% +$531K ﹤0.01% 3493
2024
Q2 		$209K Sell
24,485
-12,362
-34% -$113K ﹤0.01% 3555
2024
Q1 		$341K Sell
36,847
-27,267
-43% -$240K ﹤0.01% 3822
2023
Q4 		$622K Buy
64,114
+53,305
+493% +$498K ﹤0.01% 3749
2023
Q3 		$97K Buy
10,809
+2,430
+29% +$23.1K ﹤0.01% 3611
2023
Q2 		$94K Sell
8,379
-5,243
-38% -$46.5K ﹤0.01% 3585
2023
Q1 		$143K Buy
13,622
+6,374
+88% +$70.2K ﹤0.01% 3981
2022
Q4 		$70.1K Buy
7,248
+6,029
+495% +$67.9K ﹤0.01% 4417
2022
Q3 		$15K Sell
1,219
-175
-13% -$2.13K ﹤0.01% 4172
2022
Q2 		$14K Sell
1,394
-2,339
-63% -$25.8K ﹤0.01% 4521
2022
Q1 		$47K Buy
+3,733
New +$57K ﹤0.01% 4143

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's ENFN Position: Q2 2025 in Review

Barclays sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 84,948 shares — an estimated $947K sold.

Barclays first reported a position in ENFN in Q1 2022 and held it in 13 quarters. The position peaked at $970K in Q4 2024. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • Barclays reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 84,948 Enfusion, Inc. shares in Q2 2025, an estimated $947K.
  • Barclays first reported a position in Enfusion, Inc. in Q1 2022 and held it in 13 quarters.
  • Barclays's Enfusion, Inc. position peaked at $970K in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.